911 related articles for article (PubMed ID: 33092283)
1. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
Li J; Eu JQ; Kong LR; Wang L; Lim YC; Goh BC; Wong ALA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33092283
[TBL] [Abstract][Full Text] [Related]
2. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cell metabolism: a potential target for cancer therapy.
Deshmukh A; Deshpande K; Arfuso F; Newsholme P; Dharmarajan A
Mol Cancer; 2016 Nov; 15(1):69. PubMed ID: 27825361
[TBL] [Abstract][Full Text] [Related]
4. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
5. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
6. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria and cancer chemoresistance.
Guerra F; Arbini AA; Moro L
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
[TBL] [Abstract][Full Text] [Related]
8. The peculiarities of cancer cell metabolism: A route to metastasization and a target for therapy.
Carvalho TM; Cardoso HJ; Figueira MI; Vaz CV; Socorro S
Eur J Med Chem; 2019 Jun; 171():343-363. PubMed ID: 30928707
[TBL] [Abstract][Full Text] [Related]
9. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy.
Zois CE; Harris AL
J Mol Med (Berl); 2016 Feb; 94(2):137-54. PubMed ID: 26882899
[TBL] [Abstract][Full Text] [Related]
10. Biological role of metabolic reprogramming of cancer cells during epithelial‑mesenchymal transition (Review).
Li M; Bu X; Cai B; Liang P; Li K; Qu X; Shen L
Oncol Rep; 2019 Feb; 41(2):727-741. PubMed ID: 30483813
[TBL] [Abstract][Full Text] [Related]
11. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids.
Pranzini E; Pardella E; Paoli P; Fendt SM; Taddei ML
Trends Cancer; 2021 Aug; 7(8):682-699. PubMed ID: 33736962
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cell Metabolism as Cancer Therapy.
Ngoi NYL; Eu JQ; Hirpara J; Wang L; Lim JSJ; Lee SC; Lim YC; Pervaiz S; Goh BC; Wong ALA
Antioxid Redox Signal; 2020 Feb; 32(5):285-308. PubMed ID: 31841375
[No Abstract] [Full Text] [Related]
14. Core-shell nanoparticles suppress metastasis and modify the tumour-supportive activity of cancer-associated fibroblasts.
Kovács D; Igaz N; Marton A; Rónavári A; Bélteky P; Bodai L; Spengler G; Tiszlavicz L; Rázga Z; Hegyi P; Vizler C; Boros IM; Kónya Z; Kiricsi M
J Nanobiotechnology; 2020 Jan; 18(1):18. PubMed ID: 31964403
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming: the emerging concept and associated therapeutic strategies.
Yoshida GJ
J Exp Clin Cancer Res; 2015 Oct; 34():111. PubMed ID: 26445347
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
[TBL] [Abstract][Full Text] [Related]
17. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.
Fu R; Zhang YW; Li HM; Lv WC; Zhao L; Guo QL; Lu T; Weiss SJ; Li ZY; Wu ZQ
Br J Pharmacol; 2018 Jul; 175(14):3034-3049. PubMed ID: 29722898
[TBL] [Abstract][Full Text] [Related]
18. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
Clara JA; Monge C; Yang Y; Takebe N
Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
[TBL] [Abstract][Full Text] [Related]
19. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.
El Hassouni B; Granchi C; Vallés-Martí A; Supadmanaba IGP; Bononi G; Tuccinardi T; Funel N; Jimenez CR; Peters GJ; Giovannetti E; Minutolo F
Semin Cancer Biol; 2020 Feb; 60():238-248. PubMed ID: 31445217
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell metabolism.
Peiris-Pagès M; Martinez-Outschoorn UE; Pestell RG; Sotgia F; Lisanti MP
Breast Cancer Res; 2016 May; 18(1):55. PubMed ID: 27220421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
